PE20220144A1 - Anticuerpo monoclonal que se une especificamente a gitr - Google Patents

Anticuerpo monoclonal que se une especificamente a gitr

Info

Publication number
PE20220144A1
PE20220144A1 PE2021001765A PE2021001765A PE20220144A1 PE 20220144 A1 PE20220144 A1 PE 20220144A1 PE 2021001765 A PE2021001765 A PE 2021001765A PE 2021001765 A PE2021001765 A PE 2021001765A PE 20220144 A1 PE20220144 A1 PE 20220144A1
Authority
PE
Peru
Prior art keywords
seq
gitr
antibodies
cancer
cells
Prior art date
Application number
PE2021001765A
Other languages
English (en)
Inventor
Andrei Borisovich Ulitin
Olesya Nikolaevna Kozlova
Aleksandr Andreevich Gordeev
Ksenia Mihailovna Burnysheva
Anastasia Nikolaevna Ishutinova
Aleksandra Aleksandrovna Sozonova
Sergei Andreevich Ageev
Aleksandr Nikolaevich Doronin
Vladimir Sergeevich Tsympilov
Ivan Vladimirovich Mitroshin
Valery Vladimirovich Solovyev
Iakov Iurevich Ustiugov
Roman Alekseevich Ivanov
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of PE20220144A1 publication Critical patent/PE20220144A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a anticuerpos que se unen especificamente a GITR (proteina que pertenece a la superfamilia de receptores del factor de necrosis tumoral/TNFRSF18) o sus fragmentos de union al antigeno que comprenden: (a) un dominio variable de cadena pesada que comprende: CDR1 seleccionada de SEQ ID NO: 1 o 12, CDR2 seleccionada de SEQ ID NO: 2 o 13 y CDR3 seleccionada de SEQ ID NO: 3 o 14; (b) un dominio variable de cadena liviana que comprende: de cadena liviana que comprende: CDR1 seleccionada de SEQ ID NO: 7 o 17, CDR2 seleccionada de SEQ ID NO: 8 o 18 y CDR3 seleccionada de SEQ ID NO: 9 o 19. Tambien se refiere a un acido nucleico, un vector de expresion, una celula huesped, una composicion farmaceutica y metodos que comprenden los anticuerpos de la invencion. Mas particularmente, la presente se refiere a anticuerpos monoclonales agonistas que interactuan con GITR, se citan como efectos la mejora en la proliferacion y el funcionamiento de celulas T efectoras asi tambien, la inhibicion del efecto supresor de celulas T reguladoras; siendo utiles en el tratamiento de enfermedades o trastornos asociados con GITR tales como: cancer de cuello uterino, cancer colorrectal (CRC), cancer de ovario, cancer de pulmon de celulas no pequenas (NSCLC), entre otros.
PE2021001765A 2019-04-23 2020-04-23 Anticuerpo monoclonal que se une especificamente a gitr PE20220144A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019112296A RU2734432C1 (ru) 2019-04-23 2019-04-23 Моноклональное антитело, которое специфически связывается с GITR
PCT/RU2020/050080 WO2020218951A2 (ru) 2019-04-23 2020-04-23 Моноклональное антитело, которое специфически связывается с gitr

Publications (1)

Publication Number Publication Date
PE20220144A1 true PE20220144A1 (es) 2022-01-27

Family

ID=69821666

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001765A PE20220144A1 (es) 2019-04-23 2020-04-23 Anticuerpo monoclonal que se une especificamente a gitr

Country Status (24)

Country Link
US (1) US12410257B2 (es)
EP (1) EP3964525A4 (es)
JP (1) JP7695200B2 (es)
KR (1) KR20220010501A (es)
CN (1) CN110903392B (es)
AR (1) AR118763A1 (es)
AU (1) AU2020261207A1 (es)
BR (1) BR112021021281A2 (es)
CA (1) CA3137822A1 (es)
CL (1) CL2021002792A1 (es)
CO (1) CO2021014153A2 (es)
EA (1) EA202192907A1 (es)
IL (1) IL287531A (es)
JO (1) JOP20210286A1 (es)
MA (2) MA54969B2 (es)
MX (1) MX2021012962A (es)
MY (1) MY210018A (es)
PE (1) PE20220144A1 (es)
PY (1) PY2018606A (es)
RU (1) RU2734432C1 (es)
TW (1) TWI803718B (es)
UY (1) UY38672A (es)
WO (1) WO2020218951A2 (es)
ZA (1) ZA202109374B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2724470C1 (ru) * 2019-11-11 2020-06-23 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Применение cas9 белка из бактерии pasteurella pneumotropica для модификации геномной днк в клетках
CN111732658B (zh) * 2020-06-28 2022-04-26 英诺湖医药(杭州)有限公司 一组gitr单克隆抗体及其医药用途
CN112362876B (zh) * 2020-08-06 2023-12-15 武汉天德生物科技有限公司 一种检测早期老年痴呆症的胶体金试纸条及其制备方法
CN112540179B (zh) * 2020-08-06 2023-07-07 武汉天德生物科技有限公司 一种测试ApoE4蛋白含量的ELISA试剂盒
CN111763257B (zh) * 2020-09-01 2020-12-15 北京百奥赛图基因生物技术有限公司 抗gitr抗体及其用途
CN112646040B (zh) * 2020-12-31 2022-03-25 中元汇吉生物技术股份有限公司 特异性结合人IgG4的蛋白及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
AU2004244626A1 (en) * 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
WO2006104989A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
WO2007005612A2 (en) 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
PT3023438T (pt) * 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
DK3148579T3 (da) * 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
AU2015271709B2 (en) 2014-06-06 2020-11-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
CA2973978A1 (en) * 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
CN108473579B (zh) 2015-10-22 2022-03-01 埃博灵克斯股份有限公司 Gitr激动剂
CA3007022A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
IL263273B2 (en) 2016-06-10 2025-10-01 Regeneron Pharma Antibodies against GITR and their uses
EP3478721A1 (en) 2016-07-01 2019-05-08 Five Prime Therapeutics, Inc. Combined anti tumor therapy with a gitr agonist and cpg
JP7009448B2 (ja) 2016-08-12 2022-02-10 ヤンセン バイオテツク，インコーポレーテツド 強化されたアゴニスト活性を有する、Ｆｃが遺伝子操作を受けた抗ＴＮＦＲスーパーファミリーメンバー抗体及びその使用方法
CA3042727A1 (en) * 2016-11-19 2018-05-24 Potenza Therapeutics, Inc. Anti-gitr antigen-binding proteins and methods of use thereof
CA3049689A1 (en) 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for augmenting antibody mediated receptor signaling
KR20190124753A (ko) * 2017-03-03 2019-11-05 리나트 뉴로사이언스 코프. 항-gitr 항체 및 이의 사용 방법
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途

Also Published As

Publication number Publication date
KR20220010501A (ko) 2022-01-25
JOP20210286A1 (ar) 2021-10-24
MA55390A1 (fr) 2022-05-31
MA55390B1 (fr) 2022-10-31
TW202100554A (zh) 2021-01-01
WO2020218951A3 (ru) 2020-12-24
JP7695200B2 (ja) 2025-06-18
WO2020218951A2 (ru) 2020-10-29
EA202192907A1 (ru) 2022-01-25
CN110903392A (zh) 2020-03-24
ZA202109374B (en) 2022-12-21
CN110903392B (zh) 2024-02-13
TWI803718B (zh) 2023-06-01
US12410257B2 (en) 2025-09-09
BR112021021281A2 (pt) 2022-03-08
EP3964525A4 (en) 2022-12-28
MA54969B2 (fr) 2025-10-31
MA54969A1 (fr) 2022-08-31
PY2018606A (es) 2023-09-15
AR118763A1 (es) 2021-10-27
UY38672A (es) 2020-10-30
MY210018A (en) 2025-08-21
CO2021014153A2 (es) 2021-10-29
RU2734432C1 (ru) 2020-10-16
CL2021002792A1 (es) 2022-06-24
CA3137822A1 (en) 2020-10-29
IL287531A (en) 2021-12-01
MX2021012962A (es) 2021-12-15
EP3964525A2 (en) 2022-03-09
US20220213209A1 (en) 2022-07-07
AU2020261207A1 (en) 2021-12-23
JP2022532991A (ja) 2022-07-21

Similar Documents

Publication Publication Date Title
MX2021005708A (es) Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
PE20180046A1 (es) Anticuerpos terapeuticos y sus usos
CL2023002239A1 (es) Anticuerpos de b7-h4 y métodos para usarlos
PE20200384A1 (es) Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos
PH12021500031A1 (en) Anti-il2 receptor gamma antigen-binding proteins
PE20191487A1 (es) Anticuerpos anti-gitr y metodos de uso de los mismos
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
EA202091710A1 (ru) Антитела против cd73 и способы их применения
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
PE20240111A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
ECSP099683A (es) Proteinas de union incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos que se unen especificamente a cd154 y sus usos.
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
EA201890613A1 (ru) Полипептиды, связывающие cd3
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
PE20190737A1 (es) Anticuerpos anti-cd27
PE20211858A1 (es) Variantes de anticuerpos anti-cd38 y sus usos
AR087615A1 (es) Moleculas biespecificas de union a antigeno
EA202091747A1 (ru) Составы антитела b7-h4
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
PE20191319A1 (es) Anticuerpos novedosos contra el factor xi y sus usos
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr